EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges

Mary Kate Hart, George A Saviolakis, Susan L Welkos, Robert V House

Advances in Preventive Medicine · 2012 · 2012 · 1-14

DOI: 10.1155/2012/731604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Preventive Medicine, 2012. Verfasst von Mary Kate Hart und 3 weiteren Autor:innen. Beteiligte Einrichtung: DynPort Vaccine Company LLC, Frederick, MD 21702, USA. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Chemical Biological Medical Systems-Joint Vaccine Acquisition Program, Department of Defense, U.S. Army Medical Research and Materiel Command.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of vaccines for microorganisms and bacterial toxins with the potential to be used as biowarfare and bioterrorism agents is an important component of the US biodefense program. DVC is developing two vaccines, one against inhalational exposure to botulinum neurotoxins A1 and B1 and a second for Yersinia pestis , with the ultimate goal of licensure by the FDA under the Animal Rule. Progress has been made in all technical areas, including manufacturing, nonclinical, and clinical development and testing of the vaccines, and in assay development. The current status of development of these vaccines, and remaining challenges are described in this chapter.

Autor:innen und Institutionen

  • DynPort Vaccine Company LLC, Frederick, MD 21702, USA.

Förderung

  • Chemical Biological Medical Systems-Joint Vaccine Acquisition Program
  • Department of Defense
  • U.S. Army Medical Research and Materiel Command

Zitieren

APA

Hart, M. K., Saviolakis, G. A., Welkos, S. L., & House, R. V. (2012). Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges. Advances in Preventive Medicine, 2012, 1-14. https://doi.org/10.1155/2012/731604

Vancouver

Hart MK, Saviolakis GA, Welkos SL, House RV. Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges. Advances in Preventive Medicine. 2012;2012:1-14. doi:10.1155/2012/731604

BibTeX
@article{Hart2012,
  author = {Hart, Mary Kate and Saviolakis, George A and Welkos, Susan L and House, Robert V},
  title = {Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges},
  journal = {Advances in Preventive Medicine},
  year = {2012},
  volume = {2012},
  pages = {1--14},
  doi = {10.1155/2012/731604}
}
Kostenlos starten →